Published in Breast Cancer Res Treat on May 04, 2011
Targeting insulin and insulin-like growth factor signaling in breast cancer. J Mammary Gland Biol Neoplasia (2012) 1.08
The role of the insulin-like growth factor-1 system in breast cancer. Mol Cancer (2015) 1.05
Insulin-like growth factor-I receptor (IGF-IR) translocates to nucleus and autoregulates IGF-IR gene expression in breast cancer cells. J Biol Chem (2011) 1.03
Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance. Mol Cancer Res (2014) 0.96
Interaction between IGF-IR and ER induced by E2 and IGF-I. PLoS One (2013) 0.87
A systematic evaluation of multi-gene predictors for the pathological response of breast cancer patients to chemotherapy. PLoS One (2012) 0.86
Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model. PLoS One (2012) 0.81
Novel Aspects Concerning the Functional Cross-Talk between the Insulin/IGF-I System and Estrogen Signaling in Cancer Cells. Front Endocrinol (Lausanne) (2015) 0.81
Stromal cells promote anti-estrogen resistance of breast cancer cells through an insulin-like growth factor binding protein 5 (IGFBP5)/B-cell leukemia/lymphoma 3 (Bcl-3) axis. Oncotarget (2015) 0.80
Expression of estrogen receptors in non-malignant mammary tissue modifies the association between insulin-like growth factor 1 and breast cancer risk. Ann Oncol (2014) 0.79
Synergistic effect of fadrozole and insulin-like growth factor-I on female-to-male sex reversal and body weight of broiler chicks. PLoS One (2014) 0.78
Mechanisms of dihydrotestosterone action on resveratrol-induced anti-proliferation in breast cancer cells with different ERα status. Oncotarget (2015) 0.78
Building a successful fertility preservation program at a major cancer center. J Gynecol Oncol (2014) 0.78
Immunolocalization of insulin-like growth factor-I (IGF-I) and its receptors (IGF-IR) in the equine epididymis. J Reprod Dev (2014) 0.76
Bioavailable insulin-like growth factor-I as mediator of racial disparity in obesity-relevant breast and colorectal cancer risk among postmenopausal women. Menopause (2016) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A (2001) 68.44
A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med (2002) 58.15
Genome-wide analysis of estrogen receptor binding sites. Nat Genet (2006) 18.63
Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell (2002) 17.32
Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology (2003) 4.96
Formation of the androgen receptor transcription complex. Mol Cell (2002) 4.93
The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem (2001) 4.67
Discovery of estrogen receptor alpha target genes and response elements in breast tumor cells. Genome Biol (2004) 2.77
The adaptor protein SLP-65 acts as a tumor suppressor that limits pre-B cell expansion. Nat Immunol (2002) 2.35
The IGF system and breast cancer. Endocr Relat Cancer (2001) 2.21
Mammary gland development and tumorigenesis in estrogen receptor knockout mice. J Mammary Gland Biol Neoplasia (1997) 2.04
Enhancement of insulin-like growth factor signaling in human breast cancer: estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo. Mol Endocrinol (1999) 2.00
Genes regulated by estrogen in breast tumor cells in vitro are similarly regulated in vivo in tumor xenografts and human breast tumors. Genome Biol (2006) 1.88
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci (2008) 1.88
The gene expression response of breast cancer to growth regulators: patterns and correlation with tumor expression profiles. Cancer Res (2003) 1.81
Insulin-like growth factor physiology and cancer risk. Eur J Cancer (2000) 1.71
Requirement of estrogen receptor-alpha in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk. J Biol Chem (2001) 1.60
Insulin-like growth factor I is essential for terminal end bud formation and ductal morphogenesis during mammary development. Endocrinology (1999) 1.53
Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia. Nature (2003) 1.39
Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells. Carcinogenesis (2006) 1.37
A genomic view of estrogen actions in human breast cancer cells by expression profiling of the hormone-responsive transcriptome. J Mol Endocrinol (2004) 1.35
Global uterine genomics in vivo: microarray evaluation of the estrogen receptor alpha-growth factor cross-talk mechanism. Mol Endocrinol (2004) 1.24
Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J Biol Chem (2000) 1.24
Insulin and IGF-1 induce different patterns of gene expression in mouse fibroblast NIH-3T3 cells: identification by cDNA microarray analysis. Endocrinology (2001) 1.20
Histone deacetylase 7 and FoxA1 in estrogen-mediated repression of RPRM. Mol Cell Biol (2009) 1.15
Microarray analysis of insulin and insulin-like growth factor-1 (IGF-1) receptor signaling reveals the selective up-regulation of the mitogen heparin-binding EGF-like growth factor by IGF-1. J Biol Chem (2002) 1.10
Wnt-1 is dominant over neu in specifying mammary tumor expression profiles. Technol Cancer Res Treat (2006) 1.10
IGF-I physiology and breast cancer. Recent Results Cancer Res (1998) 1.10
Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus. Proc Natl Acad Sci U S A (1996) 1.08
Multihormonal regulation of the progesterone receptor in MCF-7 human breast cancer cells: interrelationships among insulin/insulin-like growth factor-I, serum, and estrogen. Endocrinology (1990) 1.06
Estradiol enhances the stimulatory effect of insulin-like growth factor-I (IGF-I) on mammary development and growth hormone-induced IGF-I messenger ribonucleic acid. Endocrinology (1995) 1.03
The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Breast Cancer Res (2008) 1.01
Insulin-like growth factor 1 differentially regulates estrogen receptor-dependent transcription at estrogen response element and AP-1 sites in breast cancer cells. J Biol Chem (2006) 0.96
Insulin-like growth factor-1 (IGF-1) receptor-insulin receptor substrate complexes in the uterus. Altered signaling response to estradiol in the IGF-1(m/m) mouse. J Biol Chem (1998) 0.94
Genome-wide analysis of changes in early gene expression induced by oestrogen. Genes Cells (2002) 0.93
The use of whole genome amplification to study chromosomal changes in prostate cancer: insights into genome-wide signature of preneoplasia associated with cancer progression. BMC Genomics (2006) 0.90
Role of estrogen receptor (ER) alpha in insulin-like growth factor (IGF)-I-induced responses in MCF-7 breast cancer cells. J Mol Endocrinol (2005) 0.87
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 11.93
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 8.64
Social networkers' attitudes toward direct-to-consumer personal genome testing. Am J Bioeth (2009) 8.28
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci U S A (2009) 7.95
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet (2003) 5.40
Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res (2011) 4.84
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst (2003) 4.45
Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell (2007) 4.43
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst (2005) 4.25
A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome. Genome Res (2008) 4.06
MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat (2006) 4.04
Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res (2008) 3.83
Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol (2008) 3.74
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol (2005) 3.62
Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol (2005) 3.62
Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev (2009) 3.58
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res (2010) 3.53
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science (2011) 3.49
Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res (2008) 3.45
TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature (2010) 3.37
Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell (2009) 3.36
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res (2008) 3.32
Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell (2011) 3.27
Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development (2007) 3.07
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol (2010) 2.93
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res (2013) 2.63
Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2. Cell Cycle (2007) 2.48
Research with stored biological samples: what do research participants want? Arch Intern Med (2005) 2.43
Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res (2009) 2.34
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol (2006) 2.24
Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg (2008) 2.14
COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis. Nature (2012) 2.11
Proinflammatory role for let-7 microRNAS in experimental asthma. J Biol Chem (2010) 2.08
AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Res (2004) 2.07
Global effects of virulence gene regulators in a Bacillus anthracis strain with both virulence plasmids. Infect Immun (2003) 2.05
High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A (2012) 2.03
Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc Natl Acad Sci U S A (2011) 2.01
Evidence that an early pregnancy causes a persistent decrease in the number of functional mammary epithelial stem cells--implications for pregnancy-induced protection against breast cancer. Stem Cells (2008) 1.96
A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol (2010) 1.94
Identification of genes modulated in rheumatoid arthritis using complementary DNA microarray analysis of lymphoblastoid B cell lines from disease-discordant monozygotic twins. Arthritis Rheum (2006) 1.92
The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. Front Biosci (2008) 1.88
Cleavage of fibrinogen by proteinases elicits allergic responses through Toll-like receptor 4. Science (2013) 1.87
Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Res Treat (2005) 1.85
Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α. J Natl Cancer Inst (2011) 1.84
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol (2013) 1.81
Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res (2013) 1.80
The Rexinoid LG100268 prevents the development of preinvasive and invasive estrogen receptor negative tumors in MMTV-erbB2 mice. Clin Cancer Res (2007) 1.79
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell (2016) 1.79
Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Res (2010) 1.77
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res (2008) 1.75
Comparison of OG1RF and an isogenic fsrB deletion mutant by transcriptional analysis: the Fsr system of Enterococcus faecalis is more than the activator of gelatinase and serine protease. J Bacteriol (2006) 1.71
Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotype. Clin Cancer Res (2006) 1.67
Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res (2004) 1.67
Medical complications and outcomes after hip fracture repair. Arch Intern Med (2002) 1.65
The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest (2011) 1.59
Identification of murine uterine genes regulated in a ligand-dependent manner by the progesterone receptor. Endocrinology (2005) 1.59
Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. J Clin Oncol (2005) 1.58
Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res (2005) 1.58
Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2. Mol Cell Biol (2006) 1.58
Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res (2008) 1.58
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One (2011) 1.57
β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res (2011) 1.56
Acceleration of the glycolytic flux by steroid receptor coactivator-2 is essential for endometrial decidualization. PLoS Genet (2013) 1.56
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation. Breast Cancer Res (2011) 1.54
miR-200 Inhibits lung adenocarcinoma cell invasion and metastasis by targeting Flt1/VEGFR1. Mol Cancer Res (2010) 1.54
CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors. Cell (2013) 1.53
The natural history of Unverricht-Lundborg disease: a report of eight genetically proven cases. Mov Disord (2008) 1.53
atxA controls Bacillus anthracis capsule synthesis via acpA and a newly discovered regulator, acpB. J Bacteriol (2004) 1.52
To share or not to share: a randomized trial of consent for data sharing in genome research. Genet Med (2011) 1.52
Molecular profiling of human prostate tissues: insights into gene expression patterns of prostate development during puberty. FASEB J (2004) 1.51
Retracted Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res (2010) 1.51
The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res (2002) 1.51
Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res (2009) 1.48
The p160 ER co-regulators predict outcome in ER negative breast cancer. Breast Cancer Res Treat (2011) 1.47
An injectable method for noninvasive spine fusion. Spine J (2011) 1.46